Long-term survival of 3000 transthyretin familial amyloid polyneuropathy patients over a century

T. Coelho¹,², M. Inês³, I. Conceição³,⁴, P. Saramago⁵, M. de Carvalho³,⁴, and J. Costa⁶,⁷,⁸

¹Corino de Andrade Unit, Hospital de Santo António, Centro Hospitalar do Porto, Portugal
²Department of Neurosciences, Hospital de Santo António, Centro Hospitalar do Porto, Portugal
³Faculty of Medicine, University of Lisbon, Instituto de Medicina Molecular, Portugal
⁴Department of Neurosciences, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Portugal
⁵Centre for Health Economics, University of York, UK
⁶Clinical Pharmacology Unit, Instituto de Medicina Molecular, University of Lisbon, Portugal
⁷Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal
⁸Center for Evidence Based-Medicine, Faculty of Medicine, University of Lisbon, Portugal

Correspondence: monica.s.ines@gmail.com

Abstract

Background: Comprehensive long-term survival data on transthyretin familial amyloid polyneuropathy (TTR-FAP) are scarce. We aimed to estimate long-term survival in this rare disease using data from the largest and oldest cluster of patients in the world.

Methods: Registry data from the Portuguese referral centres were merged encompassing 3,026 Val30Met patients until Dec 2015. Patient groups analysed comprised natural disease (n=1,675), treatment with liver transplant (LTx) (n=978) and disease modifying oral treatment with tafamidis (n=373). Kaplan-Meier survival estimates and Cox proportional hazards model were used to adjusted by gender, late-onset, treatment and time until treatment.

Results: Overall, long-term median survival since disease onset was 13.29 years (95%CI: 13.01-13.94); 11.55 years (95%CI: 11.01-11.99) in the natural disease and 25.07 years (95%CI: 23.23-27.25) in the LTx group. Median survival was not reached in the tafamidis group, with 5 and 10 years' survival rate of 99.70% (95%CI: 97.91%-99.96%) and 94.55% (95%CI: 85.73%-97.98%). LTx (HR 0.15, 95%CI: 0.12-0.19) and tafamidis (HR 0.04; 95%CI: 0.02-0.12) are associated with increased survival, compared with natural disease progression. Being male (HR 1.19, 95%CI: 1.08–1.31), late-onset (HR 1.46, 95%CI: 1.27–1.68) and time until treatment (HR 1.07, 95%CI: 1.03–1.10) were found to be important risk factors associated with increased mortality.

Conclusions: Long-term survival of TTR-FAP Val30Met patients is poor. Although with higher short-term mortality, LTx significantly improved long-term survival. Tafamidis is associated with higher survival though longer follow-up data is needed. Shorter time between disease onset and treatment is associated with increased survival. In case of clinical progression under drug treatment it’s important to further study how and when to cross over to other options in order to maximize long-term survival from sequential treatments.

© 2016 Coelho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.